MAP2K7 and cancer: A recent Phase I clinical study also showed that the combination of BRAF inhibitor (vemurafenib) with rapamycin (everolimus, rapamycin analogs) is safe and well tolerated, with partial responses among different cancers, including patients who previously experienced progression on BRAF and/or MEK inhibitor therapy [67].